Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GIB-1 + GI-IQ2
- Development stage
- Preclinical
- Lead developer
- GI Biome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
GIB-1 + GI-IQ2 is an experimental combination microbiome therapy being developed by GI Longevity, a subsidiary of GI Biome. This therapeutic candidate is designed as a live biotherapeutic product (LBP) that leverages the gut-immune and gut-brain axes to address age-related physiological decline. The combination utilizes GI Biome's proprietary microbial strains (the GIB series) alongside the GI-IQ2 complex, which is specifically oriented toward cognitive health and neurological support via the microbiome. The therapy aims to promote healthy aging and longevity by modulating the intestinal microbiota and its systemic metabolic and signaling outputs.
- Other names
- GI Longevity combination therapyGI-IQ2 combinationGI-IQ-2 combinationGI-IQ 2 combination
Beyond the preview
Go deeper on GIB-1 + GI-IQ2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GIB-1 + GI-IQ2.